Unknown PHASE2 INTERVENTIONAL NCT00003681

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Phase II Multicenter Study of Amifostine in Patients With Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Anemia Myelodysplastic Syndromes

Interventions amifostine trihydrate epoetin alfa

Updated 6 times since 2017 Last updated: May 9, 2009 Started: Aug 31, 1998

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anemia and Myelodysplastic Syndromes and is currently ongoing. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antwerp, Belgium , Basel, Switzerland , Bratislava, Slovakia , Bruges, Belgium , Brussels (Bruxelles), Belgium , Edegem, Belgium , Innsbruck, Austria , Leiden, Netherlands , Olomouc, Czechia , Porto, Portugal and 2 more locations